CLINICAL TRIALS PROFILE FOR TECVAYLI
All Clinical Trials for TECVAYLI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05972135 ↗ | Outpatient Administration of Teclistamab for Multiple Myeloma | Recruiting | Janssen Research & Development, LLC | Phase 2 | 2023-10-23 | This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients |
| NCT05972135 ↗ | Outpatient Administration of Teclistamab for Multiple Myeloma | Recruiting | SCRI Development Innovations, LLC | Phase 2 | 2023-10-23 | This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients |
| NCT06465316 ↗ | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | RECRUITING | National Cancer Institute (NCI) | PHASE1 | 2024-12-06 | This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TECVAYLI
Condition Name
Clinical Trial Locations for TECVAYLI
Trials by Country
Clinical Trial Progress for TECVAYLI
Clinical Trial Phase
Clinical Trial Sponsors for TECVAYLI
Sponsor Name
